Know Cancer

forgot password

A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer

Phase 2
18 Years
Not Enrolling
Hormone Refractory Prostate Cancer

Thank you

Trial Information

A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer

Inclusion Criteria:

- Males age ≥18 years.

- Histologically confirmed diagnosis of adenocarcinoma of the prostate.

- Hormone-refractory prostate cancer having progressed despite androgen deprivation
therapy that resulted in a castrated level of testosterone (<50 ng/dL) or
orchiectomy; with or without evidence of measurable or evaluable disease.

- PSA increase defined as 2 consecutive rises; first increase in PSA occurred a minimum
of 1 week from the reference value; increase in PSA should be at least 25% above the
reference value and absolute PSA value should be >5 ng/mL.

- May have received no more than 1 prior chemotherapy regimen. Prior immunomodulatory
therapy (sipuleucel-t (Provenge), interferon) is allowed.

- Must be taking a single agent LHRH agonist or antagonist, unless previously underwent

- ECOG performance status 0-2.

- Able to swallow pills.

- Able to provide written, voluntary informed consent, comply with trial procedures,
and have accessibility to the site.

Exclusion Criteria:

- Chemotherapy, antibody therapy, major surgery or irradiation within 4 weeks of
study enrollment

- Exposure to any investigational agent within 30 days of the Screening Visit.

- No prior flutamide (Eulexin) and ketoconazole use within 4 weeks, bicalutamide
(Casodex) within 6 weeks or nilutamide (Nilandron) within 6 weeks of study

- Use of Quadramet therapy during 2 months prior to study enrollment or Metastron ever.

- Prior treatment with a tyrosine kinase inhibitor.

- Subjects who have started bisphosphonate therapy within 4 weeks of study enrollment
are excluded. Subjects treated with a stable dose of a bisphosphonate for >4 weeks
and the tumor has still progressed can be enrolled in the study.

- Known CNS disease or CNS metastases.

- History of other malignancies within the last five years except curatively treated
basal cell carcinoma or superficial bladder cancer.

- Laboratory values: Screening serum creatinine greater than or equal to 1.5 x ULN,
alanine aminotransferase (ALT) greater than 3 times the upper limit of normal, total
bilirubin greater than 3 times the upper limit of normal, white blood cell (WBC)
count <3500/mm3, absolute neutrophil count <1500/mm3, hematocrit level <35% and
platelets <100,000/mm3.

- History of abnormal bleeding or use of anticoagulant therapy.

- Clinically evident congestive heart failure >class II of the New York Heart
Association (NYHA) guidelines.

- Serious, clinically significant cardiac arrhythmias, defined as the existence of an
absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.

- History of MI within 6 months or uncontrolled angina within 3 months.

- Severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes, chronic renal
disease, chronic liver disease.

- Known HIV infection.

- Uncontrolled active, infection.

- Substance abuse or any condition that might interfere with the subject's
participation in the study or in the evaluation of the study results.

- Any condition that in the opinion of the Investigator is unstable and could
jeopardize the subject's participation in the study.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate

Outcome Description:

The primary objective of this study is to determine the preliminary efficacy of administration of bafetinib in subjects with hormone-refractory prostate cancer (HRPC), as measured by the objective response rate (ORR), which is a combination of CR (PSA ≤0.12 ng/mL) and PR (≥50% reduction in PSA from baseline).

Outcome Time Frame:

At six months.

Safety Issue:


Principal Investigator

Daniel Levitt, M.D., Ph.D.

Investigator Role:

Study Director

Investigator Affiliation:

Chief Medical Officer, CytRx Corporation


United States: Food and Drug Administration

Study ID:




Start Date:

August 2010

Completion Date:

December 2011

Related Keywords:

  • Hormone Refractory Prostate Cancer
  • Hormone Refractory Prostate Cancer
  • HRPC
  • Prostatic Neoplasms



City of Hope Medical Center Duarte, California  91010